A Phase 4 Study to Assess the Impact of Patient Support Program on Health Related Quality of Life and Adherence in Subjects With Relapsing-Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart™ Device

A Phase IV Multicenter Randomized Study to Assess the Impact of a Patient Support Program (MinSupport Plus) on Health Related Quality of Life (HRQoL) and Adherence in Patients With Relapsing Remitting Multiple Sclerosis Administered Rebif® With the RebiSmart Device

This is a randomized, comparative, and multicenter study to assess the impact of a patient support program (MinSupport Plus) on health related quality of life (HRQoL) and adherence in subjects with relapsing-remitting multiple sclerosis administered Rebif® with the RebiSmart™ device.

Inclusion Criteria:

• Male or female, aged 18 or older
• A diagnosis of relapsing-remitting multiple sclerosis according to the revised McDonald Criteria (2010)
• Treatment with Rebif® 22 or 44 mcg subcutaneously three times a week in accordance to the Summary of product characteristics
• Rebif® administered by the RebiSmart™ device
• Provided a signed informed consent form

Exclusion Criteria:

• Has received any components, except for technical support, of MinSupport Plus prior to study entry
• Has difficulty reading and/or understanding Swedish
• Has a mental condition rendering the subject unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude
• No access to computer
• Participation in another clinical study